Tuesday, February 16, 2016

Lancet Oncology Publishes Results From the Phase 2 TERRAIN Trial of Enzalutamide Compared to Bicalutamide in Metastatic Castration-Resistant Prostate Cancer

... of patients with metastatic castration-resistant prostate cancer (CRPC).
Enzalutamide Mechanism of Action ... receptor signaling pathway within the tumor cell. In preclinical studies, enzalutamide ... spectrum of advanced prostate cancer as well as advanced breast cancer. The companies ...

No comments:

Post a Comment